Cancers Stocks List

Symbol Grade Name % Change
AGEN C Agenus Inc. -0.73
AGIO C Agios Pharmaceuticals, Inc. -4.16
CGEN F Compugen Ltd. -1.34
CGIX C Cancer Genetics, Inc. -6.39
CLSN C Celsion Corporation -4.09
EPZM F Epizyme, Inc. -0.83
ONCT C Oncternal Therapeutics, Inc. -2.09
HTBX D Heat Biologics, Inc. 1.85
ICAD B icad inc. 9.37
IONS F Ionis Pharmaceuticals, Inc. -1.89
MACK D Merrimack Pharmaceuticals, Inc. 0.58
ACHV C Achieve Life Sciences, Inc. -4.08
BDX D Becton, Dickinson and Company -1.50
AIM C AIM ImmunoTech Inc. -1.70
INFU D InfuSystems Holdings, Inc. -0.71
INO D Inovio Pharmaceuticals, Inc. -3.57
OPK D OPKO Health Inc. 2.71
ADXS C Advaxis, Inc. -1.35
DRNA A Dicerna Pharmaceuticals, Inc. -4.04
CBMG A Cellular Biomedicine Group, Inc. 0.00
SLRX C Salarius Pharmaceuticals, Inc. -3.49
PIRS D Pieris Pharmaceuticals, Inc. 0.00
PDSB C PDS Biotechnology Corporation -3.15
AVXL C Anavex Life Sciences Corp. 0.38
KURA F Kura Oncology, Inc. 2.29
MTP C Midatech Pharma PLC -6.47
BGNE C BeiGene, Ltd. -2.64
FLGT C Fulgent Genetics, Inc. 0.05
ZYME F Zymeworks Inc. -1.63
ATNX F Athenex, Inc. 3.37
MRSN F Mersana Therapeutics, Inc. -0.98
ALRN D Aileron Therapeutics, Inc. -0.96
NCNA D NuCana plc -1.19
CUE F Cue Biopharma, Inc. -1.51
TLSA F Tiziana Life Sciences plc 0.05
ENOB D Enochian Biosciences, Inc. -4.16
HOOK D HOOKIPA Pharma Inc. 3.26
ADPT D Adaptive Biotechnologies Corporation 1.67
IMAB A I-Mab 1.49
ORIC B Oric Pharmaceuticals, Inc. -6.79
BDXB F Becton, Dickinson and Company Depositary Shares, each Representing a 1/20th Interest in a Share of 6.00% Mandatory Convertible Preferred Stock, Series B -1.45
FMTX C Forma Therapeutics Holdings, Inc. -0.83
MDNA F Medicenna Therapeutics Corp. -1.49
HGEN D Humanigen, Inc. 5.49
GOVX C GeoVax Labs, Inc. -5.56
PMVP F PMV Pharmaceuticals, Inc. 7.85
PRLD D Prelude Therapeutics Incorporated -1.79
ONCR F Oncorus, Inc. -3.16
LIXT B Lixte Biotechnology Holdings, Inc. 48.55
BCAB C BioAtla, Inc. -0.43
EVAX F Evaxion Biotech A/S -4.79
View As Page of Charts


Recent Signals

Date Stock Signal Type
2021-02-25 ADXS Fell Below 20 DMA Bearish
2021-02-25 AGEN Non-ADX 1,2,3,4 Bullish Bullish Swing Setup
2021-02-25 AGEN 1,2,3 Pullback Bullish Bullish Swing Setup
2021-02-25 AGIO Fell Below 20 DMA Bearish
2021-02-25 AIM 20 DMA Resistance Bearish
2021-02-25 ALRN MACD Bearish Centerline Cross Bearish
2021-02-25 ALRN Lower Bollinger Band Walk Weakness
2021-02-25 ALRN Fell Below 50 DMA Bearish
2021-02-25 ATNX 200 DMA Resistance Bearish
2021-02-25 ATNX 50 DMA Resistance Bearish
2021-02-25 BCAB New 52 Week High Strength
2021-02-25 BCAB Doji - Bearish? Reversal
2021-02-25 BDX Lower Bollinger Band Walk Weakness
2021-02-25 BDX Crossed Above 200 DMA Bullish
2021-02-25 BDX Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2021-02-25 BDXB Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2021-02-25 BDXB Lower Bollinger Band Walk Weakness
2021-02-25 BDXB Spinning Top Other
2021-02-25 CGEN Volume Surge Other
2021-02-25 CGEN Expansion Breakdown Bearish Swing Setup
2021-02-25 CGEN Reversal New Lows Setup Bearish Swing Setup
2021-02-25 CGEN Lower Bollinger Band Walk Weakness
2021-02-25 CGEN Wide Range Bar Range Expansion
2021-02-25 CGIX Stochastic Buy Signal Bullish
2021-02-25 CGIX 20 DMA Support Bullish
2021-02-25 CLSN 1,2,3 Pullback Bullish Bullish Swing Setup
2021-02-25 CLSN MACD Bearish Signal Line Cross Bearish
2021-02-25 CLSN Non-ADX 1,2,3,4 Bullish Bullish Swing Setup
2021-02-25 CUE 50 DMA Resistance Bearish
2021-02-25 DRNA Shooting Star Candlestick Bearish
2021-02-25 DRNA New 52 Week High Strength
2021-02-25 DRNA New 52 Week Closing High Bullish
2021-02-25 DRNA Pocket Pivot Bullish Swing Setup
2021-02-25 ENOB 20 DMA Resistance Bearish
2021-02-25 ENOB Stochastic Reached Oversold Weakness
2021-02-25 EPZM Lower Bollinger Band Walk Weakness
2021-02-25 EPZM New 52 Week Low Weakness
2021-02-25 EPZM New 52 Week Closing Low Bearish
2021-02-25 EVAX Hot IPO Pullback Bullish Swing Setup
2021-02-25 FMTX MACD Bearish Signal Line Cross Bearish
2021-02-25 FMTX Fell Below 20 DMA Bearish
2021-02-25 FMTX 50 DMA Support Bullish
2021-02-25 FMTX Bollinger Band Squeeze Range Contraction
2021-02-25 GOVX NR7 Range Contraction
2021-02-25 HGEN Fell Below 50 DMA Bearish
2021-02-25 HGEN 1,2,3 Pullback Bullish Bullish Swing Setup
2021-02-25 HGEN Stochastic Reached Oversold Weakness
2021-02-25 HOOK Cup with Handle Other
2021-02-25 HOOK Fell Below 20 DMA Bearish
2021-02-25 HOOK Fell Below 50 DMA Bearish
2021-02-25 HTBX Fell Below 200 DMA Bearish
2021-02-25 ICAD Fell Below 20 DMA Bearish
2021-02-25 ICAD New 52 Week High Strength
2021-02-25 ICAD Wide Range Bar Range Expansion
2021-02-25 IMAB 20 DMA Support Bullish
2021-02-25 IMAB Shooting Star Candlestick Bearish
2021-02-25 IMAB Pocket Pivot Bullish Swing Setup
2021-02-25 INFU Fell Below 50 DMA Bearish
2021-02-25 IONS Fell Below 200 DMA Bearish
2021-02-25 KURA Fell Below 200 DMA Bearish
2021-02-25 MACK Stochastic Reached Oversold Weakness
2021-02-25 MACK 1,2,3 Pullback Bullish Bullish Swing Setup
2021-02-25 MDNA Fell Below 20 DMA Bearish
2021-02-25 MDNA 50 DMA Resistance Bearish
2021-02-25 MRSN 180 Bearish Setup Bearish Swing Setup
2021-02-25 MTP 50 DMA Support Bullish
2021-02-25 MTP 1,2,3 Pullback Bullish Bullish Swing Setup
2021-02-25 MTP Non-ADX 1,2,3,4 Bullish Bullish Swing Setup
2021-02-25 MTP Stochastic Reached Oversold Weakness
2021-02-25 NCNA MACD Bearish Centerline Cross Bearish
2021-02-25 NCNA Fell Below 50 DMA Bearish
2021-02-25 NCNA 200 DMA Support Bullish
2021-02-25 ONCT Fell Below 20 DMA Bearish
2021-02-25 OPK Lower Bollinger Band Walk Weakness
2021-02-25 ORIC 20 DMA Support Bullish
2021-02-25 ORIC 50 DMA Support Bullish
2021-02-25 PDSB Fell Below 20 DMA Bearish
2021-02-25 PIRS Shooting Star Candlestick Bearish
2021-02-25 PIRS 20 DMA Resistance Bearish
2021-02-25 PIRS 50 DMA Support Bullish
2021-02-25 PIRS Fell Below 200 DMA Bearish
2021-02-25 PIRS Doji - Bearish? Reversal
2021-02-25 PMVP Fell Below 20 DMA Bearish
2021-02-25 PRLD MACD Bearish Centerline Cross Bearish
2021-02-25 SLRX Fell Below 20 DMA Bearish
2021-02-25 SLRX Calm After Storm Range Contraction
2021-02-25 TLSA Narrow Range Bar Range Contraction
2021-02-25 TLSA Lower Bollinger Band Walk Weakness
2021-02-25 TLSA MACD Bearish Centerline Cross Bearish
2021-02-25 ZYME 200 DMA Resistance Bearish
2021-02-25 ZYME Fell Below 20 DMA Bearish

Recent News for Cancers Stocks

Date Stock Title
Feb 26 DRNA Dicerna Pharmaceuticals Inc (DRNA) Q4 2020 Earnings Call Transcript
Feb 26 FLGT 1 Green Flag for Fulgent Genetics
Feb 26 AGIO Premarket analyst action - healthcare
Feb 26 IONS Ionis Pharmaceuticals, Inc. 2020 Q4 - Results - Earnings Call Presentation
Feb 26 CLSN Celsion Corporation to Participate in the Virtual 33ʳᵈ Annual Roth Conference
Feb 26 OPK Pfizer, OPKO Health's somatrogon application validated in Europe
Feb 26 BGNE BeiGene closes tislelizumab collaboration and license agreement with Novartis
Feb 26 AGIO Agios Recognizes 14th Annual Rare Disease Day and Raises Awareness of Unmet Needs in Rare Hemolytic Anemias
Feb 26 BGNE BeiGene Announces Closing of Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab in North America, Europe and Japan
Feb 26 BGNE Assembly Biosciences Foregoes Vebicorvir Registration Studies For Chronic Suppressive Therapy
Feb 26 MRSN Mersana Therapeutics EPS misses by $0.10, misses on revenue
Feb 26 MRSN Mersana Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
Feb 26 MRSN Earnings Scheduled For February 26, 2021
Feb 26 ZYME Zymeworks: Moving Up On My Watch List
Feb 26 TLSA Tiziana Life Sciences Interview to Air on Bloomberg Television US on The RedChip Money Report
Feb 26 DRNA Dicerna Pharmaceuticals, Inc. (DRNA) CEO Doug Fambrough on Q4 2020 Results - Earnings Call Transcript
Feb 26 CLSN Is Celsion Stock a Buy Right Now? This Is What You Need to Know
Feb 26 AGIO Agios Pharmaceuticals Inc (AGIO) Q4 2020 Earnings Call Transcript
Feb 25 CGEN Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q4 2020 Results - Earnings Call Transcript
Feb 25 BGNE BeiGene EPS misses by $0.47, misses on revenue

Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body. These contrast with benign tumors, which do not spread to other parts of the body. Possible signs and symptoms include a lump, abnormal bleeding, prolonged cough, unexplained weight loss and a change in bowel movements. While these symptoms may indicate cancer, they may have other causes. Over 100 types of cancers affect humans.Tobacco use is the cause of about 22% of cancer deaths. Another 10% are due to obesity, poor diet, lack of physical activity or excessive drinking of alcohol. Other factors include certain infections, exposure to ionizing radiation and environmental pollutants. In the developing world, 15% of cancers are due to infections such as Helicobacter pylori, hepatitis B, hepatitis C, human papillomavirus infection, Epstein–Barr virus and human immunodeficiency virus (HIV). These factors act, at least partly, by changing the genes of a cell. Typically, many genetic changes are required before cancer develops. Approximately 5–10% of cancers are due to inherited genetic defects from a person's parents. Cancer can be detected by certain signs and symptoms or screening tests. It is then typically further investigated by medical imaging and confirmed by biopsy.Many cancers can be prevented by not smoking, maintaining a healthy weight, not drinking too much alcohol, eating plenty of vegetables, fruits and whole grains, vaccination against certain infectious diseases, not eating too much processed and red meat and avoiding too much sunlight exposure. Early detection through screening is useful for cervical and colorectal cancer. The benefits of screening in breast cancer are controversial. Cancer is often treated with some combination of radiation therapy, surgery, chemotherapy and targeted therapy. Pain and symptom management are an important part of care. Palliative care is particularly important in people with advanced disease. The chance of survival depends on the type of cancer and extent of disease at the start of treatment. In children under 15 at diagnosis, the five-year survival rate in the developed world is on average 80%. For cancer in the United States, the average five-year survival rate is 66%.In 2015, about 90.5 million people had cancer. About 14.1 million new cases occur a year (not including skin cancer other than melanoma). It caused about 8.8 million deaths (15.7% of deaths). The most common types of cancer in males are lung cancer, prostate cancer, colorectal cancer and stomach cancer. In females, the most common types are breast cancer, colorectal cancer, lung cancer and cervical cancer. If skin cancer other than melanoma were included in total new cancer cases each year, it would account for around 40% of cases. In children, acute lymphoblastic leukemia and brain tumors are most common, except in Africa where non-Hodgkin lymphoma occurs more often. In 2012, about 165,000 children under 15 years of age were diagnosed with cancer. The risk of cancer increases significantly with age, and many cancers occur more commonly in developed countries. Rates are increasing as more people live to an old age and as lifestyle changes occur in the developing world. The financial costs of cancer were estimated at $1.16 trillion USD per year as of 2010.

More about Cancers
Browse All Tags